Newsletter | December 23, 2025
FEATURED EDITORIAL
Why Do So Few Cell Therapies Make The Leap From Lab To GMP?
By Tatiana Golovina
Among other reasons, academic centers have access to sophisticated technology. In contrast, manufacturing suites must use established, validated methods.
MOST POPULAR NEWS
•
Researchers Develop Groundbreaking Blood Test For Lung Cancer
KVP International Acquires SafePath Laboratories And IVD Research
UM Health-Sparrow Installs First-Of-Its-Kind Lab Automation
Cofactor Genomics To Expand OncoPrism Immunotherapy Diagnostic Across U.S. Cancer Care Networks
Singlera Genomics Partners With University Of Pittsburgh To Advance Pancreatic Cancer Early Detection
Roche Announces U.S. Launch Of Next-Generation cobas 6800/8800 Systems And Software
BD Expands BD MAX System Menu With New IVDR-Certified VIASURE Assays
Techcyte Awarded Patent, Accelerating Development Of Digital Diagnostics
Pillar Biosciences And AstraZeneca Expand Liquid Biopsy Access Partnership To China
Trinity Biotech Expands Global Rollout Of High-Capacity Column System For FDA-Cleared HbA1c Testing Solution
